BrightSpring Health Services, Inc. Stock Price, News & Analysis

BrightSpring Health Services (NASDAQ: BTSG) priced an underwritten secondary offering of 15,000,000 common shares by selling stockholders, with no shares issued by BrightSpring and proceeds paid to the sellers. The offering is expected to close on October 22, 2025, subject to customary conditions.

Subject to closing, BrightSpring authorized a concurrent repurchase of 1,500,000 of those shares from the underwriter at the same per-share price; the underwriter will not receive fees on the repurchased shares. BofA Securities is sole book-running manager. The offering will be made by prospectus supplement under the company’s Form S-3 shelf registration.

BrightSpring Health Services (NASDAQ: BTSG) announced on October 20, 2025 that certain selling stockholders, including an affiliate of Kohlberg Kravis Roberts and certain management, intend to offer an aggregate of 15,000,000 shares of common stock in a secondary offering; no shares are being sold by BrightSpring and the selling stockholders will receive all proceeds.

The company also authorized, subject to the offering closing, a concurrent repurchase from the underwriter of up to the lesser of 10% of the shares sold or $50.0 million at the offering price; the repurchase is conditioned on closing and expected to occur simultaneously with the offering.

BrightSpring Health Services (NASDAQ: BTSG) reported preliminary Q3 2025 continuing-operations results and raised full-year 2025 guidance on Oct 20, 2025. Q3 revenues were approximately $3,334M (+28.2% YoY) and Adjusted EBITDA was ~$160M (+37.2% YoY). Q3 net income was ~$37.5M versus a loss of ~$25.7M in Q3 2024. The Company increased 2025 guidance to $12.4B–$12.7B revenue and $605M–$615M Adjusted EBITDA, excluding the Community Living business and future closed acquisitions.

Other items: pharmacy segment revenue led growth (~$2,967M Q3), leverage was ~3.31x at Sept 30, 2025, and the Company expects the Community Living divestiture to close in early Q1 2026.

BrightSpring Health Services (NASDAQ: BTSG) said it will release Q3 2025 financial results on Friday, October 31, 2025 before an earnings conference call scheduled for 8:30 a.m. ET the same day. Investors can register to participate and a live and archived webcast will be available on the company's investor relations site under Events & Presentations, where related presentation materials will be posted prior to the call.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q2 2025 financial results, with net revenue reaching $3.148 billion, up 29.1% year-over-year. The company's Adjusted EBITDA grew 28.8% to $143 million, while net income from continuing operations remained flat at $8.5 million.

The company's performance was driven by significant growth in both segments: Pharmacy Solutions revenue increased 32% to $2.79 billion, while Provider Services revenue grew 11% to $358 million. Following these results, BrightSpring raised its full-year 2025 guidance, now expecting revenue between $12.2-$12.6 billion (21.1-25.1% growth) and Adjusted EBITDA of $590-$605 million (28.2-31.5% growth).

Additionally, BrightSpring's planned divestiture of its Community Living business to Sevita, announced in January 2025, is expected to complete in Q4 2025.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled its second quarter 2025 financial results announcement for August 1, 2025. The company will release its earnings before the market opens, followed by a conference call at 8:30 a.m. ET on the same day.

Interested participants can register for the conference call online. The company will also provide a live and archived webcast of the call on its investor relations website, along with related presentation materials.

BrightSpring Health Services (NASDAQ: BTSG) announced that its specialty pharmacy subsidiary Onco360® has been selected as the national pharmacy partner for multiple new cancer and rare disease treatments. The partnership covers three newly approved therapies: GOMEKLI for neurofibromatosis type 1 patients with plexiform neurofibromas, AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. This expansion strengthens Onco360's position as a leading independent specialty pharmacy in providing access, education, data, and expert support for innovative treatments targeting serious and life-threatening conditions.

BrightSpring Health Services (NASDAQ: BTSG) has announced the pricing of a secondary offering of 14 million shares of common stock at $21.75 per share by its existing stockholders, including KKR affiliates and management members. The KKR Selling Stockholder has provided underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not receive any proceeds from the offering, as all proceeds will go to the Selling Stockholders. The offering is expected to close on June 12, 2025. Goldman Sachs, BofA Securities, Jefferies, and Morgan Stanley are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. Multiple other financial institutions are participating as bookrunners and co-managers.

BrightSpring Health Services (NASDAQ: BTSG) announced a secondary offering where certain stockholders, including KKR affiliates and management members, plan to sell 14 million shares of common stock. The KKR Selling Stockholder will grant underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not sell any shares or receive proceeds from this offering. Goldman Sachs and BofA Securities are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. The offering will be made through a shelf registration statement filed with the SEC on June 10, 2025.